Silica-based nanoparticles for sustained release of hydrophobic drug, preparation method therefor, and transdermal drug delivery system comprising same

Silica-based nanoparticles with a hollow core and silica matrix shell address the limitations of existing TDDS by preventing initial excessive release and enhancing sustained drug delivery, offering a stable and prolonged effect for hydrophobic drugs, thus overcoming the limitations of traditional administration methods.

WO2024237645A1PCT designated stage expired Publication Date: 2024-11-21MPIOS INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006490
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current transdermal drug delivery systems (TDDS) using hydrogels, microparticles, and microspheres based on polymer materials suffer from non-uniform particle size distribution, swelling, and polymer chain breakage, leading to initial excessive drug release and short duration of drug effect, whereas traditional administration methods like oral and parenteral have their own set of disadvantages such as first-pass effects, gastrointestinal issues, and risk of complications.

Method used

Development of silica-based nanoparticles with a hollow core and silica matrix shell for sustained release of hydrophobic drugs, where the nanoparticles are manufactured through a method involving stirring a solvent and surfactant, adding a silica precursor for hydrothermal synthesis, drying, and firing, followed by impregnation with a hydrophobic drug solution to prevent initial excessive release and enhance sustained delivery.

Benefits of technology

The silica-based nanoparticles effectively prevent initial excessive drug release and improve sustained release, providing a stable and prolonged drug delivery profile without the drawbacks of traditional methods, making them suitable for transdermal administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006490_21112024_PF_FP_ABST
    Figure KR2024006490_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to implement a hydrophobic drug as a transdermal drug delivery system (TDDS). The present invention relates to: silica-based nanoparticles for the sustained release of a hydrophobic drug, the silica-based nanoparticles comprising hollow nanoparticles that include a hollow core layer and a silica matrix shell layer, and the hydrophobic drug loaded into the hollow nanoparticles; a method for preparing same; and a transdermal drug delivery system comprising same.
Need to check novelty before this filing date? Find Prior Art

Description

Silica-based nanoparticles for sustained release of hydrophobic drugs, method for preparing the same, and transdermal drug delivery system comprising the same

[0001] The present invention relates to silica-based nanoparticles for sustained release of hydrophobic drugs, a method for preparing the same, and a transdermal drug delivery system comprising the same.

[0002] Drug administration methods include oral and parenteral administration, such as intravenous or subcutaneous injection. Oral administration is relatively easy to administer, available in tablet, capsule, or liquid forms. It is inexpensive and convenient, requiring no administration equipment or specialized assistance. However, oral administration can be affected by factors such as gastric acidity and gastric motility. Furthermore, the first-pass effect can lead to inconsistent drug concentrations in the bloodstream, potentially reducing therapeutic efficacy. An additional drawback is the risk of gastrointestinal disorders such as gastric ulcers and perforation when administered orally, including nonsteroidal anti-inflammatory drugs, narcotic analgesics, and antibiotics.

[0003] Parenteral administration methods have the disadvantages of causing allergic reactions such as hives and swelling, tissue damage, pain, bleeding, discomfort during administration, embolism if there are air bubbles in the syringe, and serious complications such as sepsis due to the risk of infection at the injection site or in the bloodstream.

[0004] Meanwhile, transdermal drug delivery systems (TDDS) have made significant strides since the first motion sickness patch received FDA approval in 1979, addressing the shortcomings of oral and parenteral administration. TDDS delivers medication directly through the skin, eliminating the first-pass effect and the risk of gastrointestinal problems. Its noninvasive nature also eliminates discomfort, pain, and the risk of embolism or sepsis.

[0005] However, paradoxically, commercial patches and ointments do not show superior performance compared to oral or parenteral administration methods in sustained release and duration, which are the greatest characteristics of TDDS. Currently, most commercial transdermal drug delivery systems are developed in the form of hydrogels, microparticles, and microspheres based on polymers such as PEG, PVA, HA, and chitosan. However, due to the nature of polymers, the particle size distribution is non-uniform, and excessive drug is released at once during the initial stage of administration due to swelling or polymer chain breakage, which raises concerns about side effects, and the duration of the drug effect is short.

[0006] [Prior Art Literature]

[0007] [Patent Document]

[0008] (Patent Document 1) Republic of Korea Patent Publication No. 10-2020-0091682 (July 31, 2020)

[0009] The present invention is intended to implement a hydrophobic drug as a transdermal drug delivery system (TDDS), and provides a silica-based nanoparticle for sustained release of a hydrophobic drug, including a hollow nanoparticle comprising a hollow core layer and a silica matrix shell layer; and a hydrophobic drug loaded in the hollow nanoparticle.

[0010] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0011] The present invention provides a silica-based nanoparticle for sustained release of a hydrophobic drug, comprising a hollow nanoparticle comprising a hollow core layer and a silica matrix shell layer; and a hydrophobic drug loaded in the hollow nanoparticle.

[0012] The above hydrophobic drug may be BCS Class II; or BCS Class IV.

[0013] The size of the hollow core layer may be 100 to 600 nm, and the size of the hollow nanoparticle may be 200 to 900 nm.

[0014] In one embodiment of the present invention, a method for producing silica-based nanoparticles for sustained release of a hydrophobic drug is provided, comprising: (a) preparing a uniform phase by stirring a solvent and a surfactant; (b) adding a silica precursor to the uniform phase prepared in step (a), performing a first reaction, and then producing nanoparticles through a hydrothermal synthesis reaction at a temperature higher than the first reaction temperature; (c) drying and calcining the nanoparticles produced in step (b) to produce hollow nanoparticles; and (d) impregnating the hollow nanoparticles produced in step (c) with a hydrophobic drug solution to load the hydrophobic drug onto the hollow nanoparticles.

[0015] In the above step (a), the solvent may be at least one selected from the group consisting of water, C1 to C4 lower alcohols, and ammonia water; and the surfactant may be at least one selected from the group consisting of cetyltrimethylammonium bromide (CTAB), 1,3,5-trimethylbenzene (1,3,5-TMB), Pluronic P123 (P123), Pluronic F127 (F127), benzene, and toluene.

[0016] In the above step (a), the content of the surfactant may be 0.5 g to 50 g based on a total of 1 L of solvent.

[0017] In the above step (b), the silica precursor may be tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS).

[0018] In the above step (b), the hydrothermal synthesis reaction can be performed at a temperature of 80 to 200°C for 24 to 168 hours.

[0019] In the above step (c), drying may be performed at a temperature of 80 to 120°C for 1 to 24 hours, and calcination may be performed at a temperature of 300 to 700°C for 3 to 12 hours.

[0020] In another embodiment of the present invention, a transdermal drug delivery system comprising silica-based nanoparticles for sustained release of the hydrophobic drug is provided.

[0021] The silica-based nanoparticle for sustained release of a hydrophobic drug according to the present invention is characterized by comprising a hollow nanoparticle including a hollow core layer and a metal-penetrated silica matrix shell layer; and a hydrophobic drug loaded in the hollow nanoparticle.

[0022] In the present invention, hollow nanoparticles are manufactured from silica, an inorganic material, and are used as a drug delivery platform, so that they are not easily hydrated or react with water under hydrophilic conditions, and their physical properties, such as specific surface area and pore volume, can be flexibly changed, so that a large amount of drug can be loaded.

[0023] In particular, it has the advantage of enabling the implementation of hydrophobic drugs as transdermal drug delivery systems (TDDS) because it can improve the release duration while preventing initial excessive release of hydrophobic drugs.

[0024] Figures 1(a) to (c) are TEM photographs of silica nanoparticles of Examples 1 to 3.

[0025] Figure 2 is a schematic diagram showing the drug release pattern from the mesoporous silica particles of the present invention.

[0026] FIG. 3(a) is a graph showing the results of drug release analysis of ibuprofen as a hydrophobic drug loaded on silica nanoparticles of Examples 1 to 3, FIG. 3(b) is a graph showing the results of drug release analysis of ibuprofen salt as a hydrophilic drug loaded on silica nanoparticles of Example 1, and FIG. 3(c) is a graph showing the results of drug release analysis of loxoprofen salt as a hydrophilic drug loaded on silica nanoparticles of Example 2.

[0027] Figure 4 is a graph showing the results of drug release analysis of ketoprofen, a hydrophobic drug loaded on silica nanoparticles of Example 3.

[0028] The present inventors prepared hollow nanoparticles by hydrothermal synthesis after adding a silica precursor to a homogeneous phase stirred with an optimal solvent and an optimal surfactant, and then confirmed that various drugs could be successfully loaded and hydrophobic drugs could be released in a sustained manner, thereby completing silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention.

[0029]

[0030] Hereinafter, the present invention will be described in detail.

[0031]

[0032] Silica-based nanoparticles and transdermal drug delivery systems for sustained release of hydrophobic drugs

[0033]

[0034] The present invention provides a silica-based nanoparticle for sustained release of a hydrophobic drug, comprising a hollow nanoparticle comprising a hollow core layer and a silica matrix shell layer; and a hydrophobic drug loaded in the hollow nanoparticle.

[0035] In addition, the present invention provides a transdermal drug delivery system comprising silica-based nanoparticles for sustained release of the hydrophobic drug.

[0036]

[0037] First, the silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention include hollow nanoparticles including a hollow core layer and a silica matrix shell layer.

[0038] Specifically, the hollow nanoparticles include a hollow core layer and a silica matrix shell layer.

[0039] The above hollow core layer may be a layer formed when a surfactant located in the core is removed during the process of drying and calcining the nanoparticles.

[0040] The size of the hollow core layer may be 100 to 600 nm, preferably 120 to 500 nm, or 150 to 300 nm, but is not limited thereto. The size of the hollow core layer can be controlled by the type and content of the surfactant. In order to effectively prevent the initial excessive release of the hydrophobic drug described below, the size of the hollow core layer is most preferably controlled to 150 to 200 nm.

[0041] The above silica matrix shell layer is a layer formed through hydrothermal synthesis of a silica precursor, and a large number of pores can be formed.

[0042] The size of the above hollow nanoparticles may be 200 to 900 nm, preferably 200 to 800 nm, 200 to 700 nm, 200 to 600 nm, 200 to 500 nm or 250 to 400 nm, but is not limited thereto.

[0043] Meanwhile, the hollow nanoparticles have a specific surface area of ​​100 to 1,000 m 2 / g can be 100 to 300 m 2 / g is preferable, but is not limited thereto. In addition, the hollow nanoparticles have a pore volume and pore size of 0.1 to 2.0 cm, respectively. 3 / g and can be 1 to 15 nm, and 0.2 to 1.0 cm 3 / g and 1 to 10 nm is preferred, but is not limited thereto.

[0044]

[0045] Next, the silica-based nanoparticles for sustained release of a hydrophobic drug according to the present invention include a hydrophobic drug, which is characterized in that it is supported on the hollow nanoparticles.

[0046] The above hydrophobic drug is in a form with low solubility, preferably BCS Class II or BCS Class IV, but is not limited thereto. The BCS class is a methodology for classifying drugs according to their solubility and permeability. Here, low solubility means that the volume of an aqueous solution sufficient to dissolve a single maximum dose of a general oral solid preparation containing the same main ingredient in a pH range of 1.2 to 6.8 exceeds 250 mL. BCS Class II refers to a group with low solubility but high permeability, and BCS Class IV refers to a group with both low solubility and low permeability. Specifically, the hydrophobic drug may be a BCS class II drug such as Ibuprofen, Ketoprofen, Loxoprofen, Diclofenac, Rotigotine, Griseofulvin, Itraconazole, Ketoconazole, Tacrolimus, Nifedipine, Carbamazepine, or the like, or may be a BCS class IV drug such as Furosemide, Hydrochlorothiazide, Cyclosporin A, Paclitaxel, Albendazole, Azathioprine, Didanosine, or the like. In the salt form of these hydrophobic drugs, they can be classified as hydrophilic drugs.

[0047] The hydrophobic drug can be efficiently loaded into the hollow nanoparticles and then have improved release duration without initial excessive release through interaction with the hollow nanoparticles with enhanced hydrophobicity.

[0048]

[0049] Meanwhile, the silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention have the advantage of improving the release duration while preventing initial excessive release of hydrophobic drugs when implemented as a transdermal drug delivery system.

[0050] Specifically, the amount of the hydrophobic drug loaded relative to the silica nanoparticles may be 10 to 90 wt%, preferably 30 to 80 wt% or 40 to 60 wt%, but is not limited thereto.

[0051] When the above silica nanoparticles are subjected to a dissolution test in SBF solution at a temperature of 32°C and a paddle speed of 600 rpm in accordance with the specifications of the in vitro skin absorption test guideline (Ministry of Food and Drug Safety), the dissolution rate of the hydrophobic drug (particularly, ibuprofen, ketoprofen) after 40 hours may be 60% or less, and is preferably 10 to 50% or 20 to 40%, but is not limited thereto.

[0052]

[0053] As reviewed above, the silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention are characterized by including hollow nanoparticles comprising a hollow core layer and a metal-penetrated silica matrix shell layer; and a hydrophobic drug loaded in the hollow nanoparticles.

[0054] In the present invention, hollow nanoparticles are manufactured from silica, an inorganic material, and are used as a drug delivery platform, so that they are not easily hydrated or react with water under hydrophilic conditions, and their physical properties, such as specific surface area and pore volume, can be flexibly changed, so that a large amount of drug can be loaded.

[0055] In particular, it has the advantage of enabling the implementation of hydrophobic drugs as transdermal drug delivery systems (TDDS) because it can improve the release duration while preventing initial excessive release of hydrophobic drugs.

[0056]

[0057] Method for preparing silica-based nanoparticles for sustained release of hydrophobic drugs

[0058]

[0059] The present invention provides a method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, comprising the steps of: (a) preparing a uniform phase by stirring a solvent and a surfactant; (b) adding a silica precursor to the uniform phase prepared in step (a), performing a first reaction, and then producing nanoparticles through a hydrothermal synthesis reaction at a temperature higher than the first reaction temperature; (c) drying and calcining the nanoparticles produced in step (b) to produce hollow nanoparticles; and (d) impregnating the hollow nanoparticles produced in step (c) with a hydrophobic drug solution to load the hydrophobic drug onto the hollow nanoparticles.

[0060]

[0061] First, the method for manufacturing silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention includes a step [step (a)] of preparing a uniform phase by stirring a solvent and a surfactant.

[0062] The solvent is for uniformly dissolving the surfactant, and may be at least one selected from the group consisting of water, lower alcohols having C1 to C4, and ammonia water. It is preferred to include all of water, lower alcohols having C1 to C4 (e.g., ethanol), and ammonia water, but is not limited thereto. Specifically, the volume ratio of the water, lower alcohols having C1 to C4 (e.g., ethanol), and ammonia water may be 10:5:1 to 50:15:1, and is preferably 20:8:1 to 30:10:1, but is not limited thereto.

[0063] In addition, the surfactant may be at least one selected from the group consisting of cetyltrimethylammonium bromide (CTAB), 1,3,5-trimethylbenzene (1,3,5-TMB), Pluronic P123 (P123), Pluronic F127 (F127), benzene, and toluene, and is preferably at least two selected from the group consisting of cetyltrimethylammonium bromide (CTAB), 1,3,5-trimethylbenzene (1,3,5-TMB), and Pluronic P123 (P123), but is not limited thereto.

[0064] Specifically, when the surfactants are three types, such as 1,3,5-TMB, CTAB, and P123, the weight ratio of 1,3,5-TMB, CTAB, and P123 may be 1:2:10 to 1:10:30, and preferably 1:2:20 to 1:3:30, but is not limited thereto. At this time, based on the total amount of 1 L of the solvent, the total content of these surfactants may be 0.5 g to 10 g. Meanwhile, when the surfactants are two types, such as 1,3,5-TMB and P123, the weight ratio may be 1:10 to 1:20. At this time, based on the total amount of 1 L of the solvent, the total content of these surfactants may be 10 g to 50 g.

[0065] The type and content of these surfactants can control the size of the hollow core layer and the size of the nanoparticles.

[0066]

[0067] Next, the method for manufacturing silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention includes a step [step (b)] of introducing a silica precursor into the prepared uniform phase, performing a first reaction, and then manufacturing nanoparticles through a hydrothermal synthesis reaction at a temperature higher than the first reaction temperature.

[0068] The above silica precursor may be tetraethylorthosilicate (TEOS) or tetramethylorthosilicate (TMOS).

[0069] The above first reaction can be carried out at room temperature for 1 to 10 hours, and can be carried out at room temperature for 2 to 7 hours.

[0070] After the above first reaction, the hydrothermal synthesis reaction can be performed in an autoclave, and can be performed at a temperature of 80 to 200°C for 24 to 168 hours, and is preferably performed at a temperature of 80 to 180°C, 80 to 160°C, 80 to 140°C, 80 to 130°C, 100 to 200°C, 100 to 180°C, 100 to 160°C, 100 to 140°C, 100 to 130°C, 120 to 200°C, 120 to 180°C, 120 to 160°C, 120 to 140°C, or 120 to 130°C for 36 to 72 hours, but is not limited thereto.

[0071] After the above hydrothermal synthesis reaction, processes such as reduced pressure filtration and distilled water washing can be added.

[0072]

[0073] Next, the method for manufacturing silica-based nanoparticles for sustained release of hydrophobic drugs according to the present invention includes a step [step (c)] of manufacturing hollow nanoparticles by drying and then calcining the manufactured nanoparticles.

[0074] Through the above drying and firing, the surfactant located in the core can be removed, thereby forming the hollow core layer.

[0075] The above drying can be performed at a temperature of 80 to 120°C for 1 to 24 hours, and is preferably performed at a temperature of 90 to 110°C for 6 to 24 hours, but is not limited thereto.

[0076] Thereafter, the above-mentioned calcination can be performed at a temperature of 300 to 700°C for 1 to 24 hours, and is preferably performed at a temperature of 400 to 600°C for 1 to 12 hours, but is not limited thereto.

[0077]

[0078] Next, the method for manufacturing silica-based nanoparticles for sustained release of a hydrophobic drug according to the present invention includes a step [step (d)] of impregnating the manufactured hollow nanoparticles into a hydrophobic drug solution to load the hydrophobic drug onto the hollow nanoparticles.

[0079] The hydrophobic drug solution may include a solvent capable of dissolving the hydrophobic drug (e.g., ethanol), and the impregnation may be performed through an incipient wetness impregnation method or an excess water impregnation method known in the art.

[0080]

[0081] Hereinafter, the present invention will be described in more detail through examples and test examples. However, the following examples and test examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.

[0082]

[0083] Example 1. Preparation of silica nanoparticles (1)

[0084] 125 ml of distilled water to be used as a solvent, 75 ml of ethanol, 15 ml of ammonia water (25-28%), and 0.105 g of CTAB (cetyltrimethylammonium bromide), 1.045 g of P123 (Pluronic P123), and 0.042 g of 1,3,5-TMB (1,3,5-trimethylbenzene) as surfactants were placed in a round-bottom flask and stirred for 3 hours to prepare a solution with a uniform phase. After adding 10 ml of TEOS (tetraethoxysilane), a silica precursor, the mixture was reacted at room temperature for 5 hours, and then treated in an autoclave at 130 °C for 48 hours. The treated solution was filtered under reduced pressure and washed with distilled water to obtain silica nanoparticles. The obtained silica nanoparticles were dried in an oven at 100 °C for 12 hours and then calcined at 500 °C for 6 hours.

[0085]

[0086] Example 2. Preparation of silica nanoparticles (2)

[0087] 125 ml of distilled water to be used as a solvent, 75 ml of ethanol, 15 ml of ammonia water (25-28%), and 0.3 g of CTAB, 0.85 g of P123, and 0.051 g of 1,3,5-TMB as surfactants were placed in a round-bottom flask and stirred for 3 hours to prepare a solution with a uniform phase. 10 ml of TEOS as a silica precursor was added, and the mixture was reacted at room temperature for 5 hours, then treated in an autoclave at 130 ° C for 48 hours. The treated solution was filtered under reduced pressure and washed with distilled water to obtain silica nanoparticles. The obtained silica nanoparticles were dried in an oven at 100 ° C for 12 hours and then calcined at 500 ° C for 6 hours.

[0088]

[0089] Example 3. Preparation of silica nanoparticles (3)

[0090] 125 ml of distilled water to be used as a solvent, 75 ml of ethanol, 15 ml of ammonia water (25-28%), 4.0 g of P123 as a surfactant, and 0.3 g of 1,3,5-TMB were placed in a round-bottom flask and stirred for 3 hours to prepare a solution with a uniform phase. 10 ml of TEOS as a silica precursor was added, and the mixture was reacted at room temperature for 5 hours, then treated in an autoclave at 130°C for 48 hours. The treated solution was filtered under reduced pressure and washed with distilled water to obtain silica nanoparticles. The obtained silica nanoparticles were dried in an oven at 100°C for 12 hours and then calcined at 500°C for 6 hours.

[0091]

[0092] Experimental Example 1. Analysis of silica nanoparticles (1) to (3)

[0093] The particle size, hollow size, shell thickness, surface area, pore volume, and pore size of the silica nanoparticles of Examples 1 to 3 were measured and are listed in Table 1 below. In addition, TEM images were taken and are shown in Figs. 1(a) to (c).

[0094] ClassificationParticle size(nm)Hollow size(nm)Shell size(nm)Surface area(m) 2 / g)Pore volume(cm 3 / g)Pore size (nm)Example 1374 ± 25182 ± 2096 ± 152820.277Example 2383 ± 40254 ± 3564 ± 82080.3510Example 3285 ± 75197 ± 6055 ± 181900.26

[0095]

[0096] Experimental Example 2. Hydrophobic Drug (1) Loading Experiment

[0097] As a hydrophobic drug, 1 g of ibuprofen was dissolved in ethanol to make 20 ml, and 1 g of silica nanoparticles prepared in Example 1 or 2 was added thereto and stirred at room temperature for 24 hours. Thereafter, the drug-loaded silica nanoparticles were filtered under reduced pressure, washed with ethanol, and dried under reduced pressure at 60°C for 4 hours. At this time, the drug loading amount was confirmed by measuring the concentration of the drug dissolved in the washing solution using a UV measuring device. A schematic diagram of the drug release pattern is shown in Figure 2. The drug loading amount was measured and is shown in Table 2 below.

[0098] Ibuprofen loading capacity per 1g of old lost ricin (g) Example 10.408 Example 20.571

[0099]

[0100] Experimental Example 3. Hydrophobic Drug (2) Loading Experiment

[0101] As a hydrophobic drug, 1 g of ketoprofen was dissolved in ethanol to make 20 ml, and 1 g of silica nanoparticles prepared in Example 3 were added thereto, followed by stirring at room temperature for 24 hours. The drug-loaded silica nanoparticles were then filtered under reduced pressure, washed with ethanol, and dried under reduced pressure at 60°C for 4 hours. At this time, the drug loading amount was confirmed by measuring the concentration of the drug dissolved in the washing solution using a UV measuring device. The drug loading amount was measured and is shown in Table 2 below.

[0102] Ketoprofen loading amount (g) per 1g of old lost licaine Example 30.554

[0103]

[0104] Experimental Example 4. Hydrophobic Drug (1) Release Experiment

[0105] As a hydrophobic drug, about 0.004 g of silica nanoparticles of Examples 1 to 3 loaded with ibuprofen were added with an appropriate amount of distilled water to form a paste, and then a membrane (artificial skin, area: 1.13 cm) was formed. 2) was applied flat on the upper surface. The membrane coated with silica paste was placed on the FDC (Franz diffusion cell) and fixed with a clamp so that it would not move. The receptor chamber was filled with SBF (simulated body fluid) solution and stirred at 32°C and 600 rpm, and 3 ml of the solution was taken at predetermined time intervals and the UV absorbance was measured to confirm the concentration of the released drug. At this time, new SBF in an amount equal to the volume of the solution taken for sampling was filled into the receptor chamber.

[0106] Meanwhile, an experiment was conducted using the silica nanoparticles of Example 1 loaded with an ibuprofen salt, a hydrophilic drug, as Comparative Example 1 using the same method. In addition, an experiment was conducted using the silica nanoparticles of Example 2 loaded with a loxoprofen salt, a hydrophilic drug, as Comparative Example 2 using the same method.

[0107] As a control group, a membrane (artificial skin, area: 1.13 cm) 2 ) were attached to the membrane. The experiment was conducted in the same manner, except that the membrane with commercial products A and B attached was placed on the FDC and fixed with a clamp to prevent movement.

[0108] The drug release amount was measured and shown in Figs. 3(a) to (c). As shown in Figs. 3(a) to (c), the in-vitro release experiment results for commercial products A and B confirmed that almost all the drug was released within about 40 hours, but ibuprofen, as a hydrophobic drug supported on the hollow mesoporous silica of Examples 1 and 2 of the present invention, was confirmed to have sustained release even after hundreds of hours while undergoing initial sustained release without an initial burst. In other words, it was confirmed that ibuprofen, as a hydrophobic drug supported on the hollow mesoporous silica of Examples 1 and 2 of the present invention, exhibited both sustained release and sustained release.

[0109] However, in the case of comparative examples 1 and 2, it was confirmed that there was a problem of initial burst rather than commercial product A.

[0110]

[0111] Experimental Example 5. Hydrophobic Drug (2) Release Experiment

[0112] As a hydrophobic drug, about 0.002 g of silica nanoparticles of Example 3 loaded with ketoprofen were added with an appropriate amount of distilled water to form a paste, and then a membrane (artificial skin, area: 1.13 cm) was formed. 2 ) was applied flat on the upper surface. The membrane coated with silica paste was placed on the FDC (Franz diffusion cell) and fixed with a clamp so that it would not move. The receptor chamber was filled with SBF (simulated body fluid) solution and stirred at 32°C and 600 rpm, and 3 ml of the solution was taken at predetermined time intervals and the UV absorbance was measured to confirm the concentration of the released drug. At this time, new SBF in an amount equal to the volume of the solution taken for sampling was filled into the receptor chamber.

[0113] As a control group, a membrane (artificial skin, area: 1.13 cm)2 ) was attached to the membrane. The experiment was performed in the same manner, except that the membrane with the commercial product C attached was placed on the FDC and fixed with a clamp to prevent movement.

[0114] The drug release amount was measured and shown in Fig. 4. As shown in Fig. 4, the in-vitro release experiment results for commercial product C confirmed that almost all the drug was released within about 40 hours, but ketoprofen, as a hydrophobic drug supported on the hollow mesoporous silica of Example 3 of the present invention, was confirmed to have sustained release even after hundreds of hours while undergoing initial sustained release without an initial burst. In other words, it was confirmed that ketoprofen, as a hydrophobic drug supported on the hollow mesoporous silica of Example 3 of the present invention, exhibited both sustained release and sustained release.

[0115]

[0116] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single entity may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined manner.

[0117] The scope of the present invention is indicated by the claims set forth below, and all changes or modifications derived from the meaning and scope of the claims and their equivalent concepts should be interpreted as being included in the scope of the present invention.

Claims

1. Hollow nanoparticles comprising a hollow core layer and a silica matrix shell layer; and Silica-based nanoparticles for sustained release of a hydrophobic drug, comprising a hydrophobic drug loaded in the hollow nanoparticles.

2. In paragraph 1, Silica-based nanoparticles for sustained release of a hydrophobic drug, characterized in that the hydrophobic drug is BCS Class II; or BCS Class IV.

3. In paragraph 1, A silica-based nanoparticle for sustained release of a hydrophobic drug, characterized in that the size of the hollow core layer is 100 to 600 nm and the size of the hollow nanoparticle is 200 to 900 nm. 4.(a) A step of preparing a uniform phase by stirring the solvent and surfactant; (b) a step of introducing a silica precursor into the uniform phase prepared in step (a) and performing a first reaction, and then manufacturing nanoparticles through a hydrothermal synthesis reaction at a temperature higher than the first reaction temperature; (c) a step of drying and calcining the nanoparticles manufactured in step (b) to manufacture hollow nanoparticles; and (d) A method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, comprising the step of impregnating the hollow nanoparticles produced in step (c) into a hydrophobic drug solution to load the hydrophobic drug onto the hollow nanoparticles.

5. In paragraph 4, A method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, characterized in that in the step (a), the solvent is at least one selected from the group consisting of water, lower alcohols of C1 to C4, and ammonia water; and the surfactant is at least one selected from the group consisting of cetyltrimethylammonium bromide (CTAB), 1,3,5-trimethylbenzene (1,3,5-TMB), Pluronic P123 (P123), Pluronic F127 (F127), benzene, and toluene.

6. In paragraph 4, A method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, characterized in that the content of the surfactant is 0.5 g to 50 g based on a total of 1 L of solvent in the above step (a).

7. In paragraph 4, A method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, characterized in that the silica precursor in the step (b) is tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS).

8. In paragraph 4, A method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, characterized in that the hydrothermal synthesis reaction in the above step (b) is performed at a temperature of 80 to 200°C for 24 to 168 hours.

9. In paragraph 4, A method for producing silica-based nanoparticles for sustained release of a hydrophobic drug, wherein in the step (c) above, drying is performed at a temperature of 80 to 120°C for 1 to 24 hours, and calcination is performed at a temperature of 300 to 700°C for 3 to 12 hours.

10. A transdermal drug delivery system comprising silica-based nanoparticles for sustained release of a hydrophobic drug according to any one of claims 1 to 3.

Citation Information

Patent Citations

  • Porous hollow silica nanoparticles, methods for producing the same, drug delivery systems and pharmaceutical compositions containing the same

    JP2010509404A

  • Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof

    KR1020140103914A

  • A facile one-pot method for nanostructure engineering of mesoporous zinc silicate particles

    KR1020160107548A

  • Hollow silica particles, compositions comprising them, and methods for making same

    US20070036736A1

  • Composition, particulate materials and methods for making particulate materials

    US20220388846A1